ESH Video

#ESHAML2023 HURRY UP: 1 WEEK LEFT TO SUBMIT YOUR ABSTRACT

August 02, 2023

 

6th International Conference

ACUTE MYELOID LEUKEMIA “MOLECULAR AND TRANSLATIONAL”:
ADVANCES IN BIOLOGY AND TREATMENT

 

October 29-31, 2023

Estoril, Portugal - #ESHAML2023

 

 


 

HURRY UP, THERE IS ONLY 1 WEEK LEFT TO SUBMIT YOUR ABSTRACT*


DO NOT MISS THE OPPORTUNITY:

 

Extended deadline: August 10th, 2023 (23:59 CEST)

*Abstracts are eligible to be selected for a poster presentation.

 



About the Conference:

The successful biannual ESH Conferences on Acute Myeloid Leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation. Novel technological, molecular and immunologic approaches are rapidly creating novel insights into the biology and therapeutic perspectives of AML.

The cutting-edge program of the conference will deal with the molecular and functional features of leukemic stem cells and their interaction with the microenvironment, the role of somatic and germ-line mutations and epigenetic alterations in the biology of AML, the genomics of leukemogenesis, advances in molecular diagnostics and developmental therapeutics with a focus on molecular and immunotherapeutic targeted therapeutics.

Special attention will be given to the utility and promise of novel therapeutic agents.

 

 


 

This meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior scientists and clinicians (MD, PhD)
• PhD candidates and clinical residents still in-training

 

 


 

MAIN SCIENTIFIC TOPICS

• Preleukemic hematopoiesis and clonal diversity
• Preleukemic conditions and predisposition
• Epigenetics
• MDS / Secondary leukemia
• Immune targeting
• Therapeutic targeting

 


LEARNING OBJECTIVES

1. Understand the pathobiology of leukemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways.
2. Acquire insight into the possible mechanisms of inherited and preleukemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.
3. Understand the characterization of a leukemia stem cell and its relationship to disease development and phenotype.
4. Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia and its clinical impact.
5. Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions.
6. Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, drug resistance mechanisms, the current developmental status of various targeted drugs and novel antibody-based and cell-transfer based immunotherapeutic approaches and their promises for future clinical application.

 

MORE INFORMATION

 


 

With the support of*:
 

Diamond Conference Partner
*******

 

Roche

Ruby Conference Partner
*******

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.